Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.

ABSTRACT:

Background

The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] > 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatectomy following adjuvant apalutamide and androgen-deprivation therapy. In this substudy, relugolix, an oral gonadotropin-releasing hormone antagonist, was evaluated in combination with apalutamide.

Objective

The aim of this study was to evaluate whether the approved standard maintenance dose of relugolix in combination with apalutamide sustains castrate testosterone levels (< 50 ng/dL).

Patients and methods

Twelve patients with HR-LPC who met all the main study criteria were included in the substudy. Patients re

SUBMITTER: Brown G 

PROVIDER: S-EPMC9928932 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature